– Collaboration leverages Cartography’s cutting-edge ATLAS and SUMMIT platforms to identify tumor-selective antigens; Pfizer to lead therapeutic development – – Cartography to receive upfront, ...
Financing led by Pfizer Ventures will support advancement of lead program CBI-1214 into a Phase 1 trial, targeted for enrollment in early 2026, and expand next wave of programs from the ATLAS and ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results